<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: Bipolar radiofrequency ablation (BRFA) of <z:mpath ids='MPATH_352'>hepatic tumors</z:mpath> has short ablation times and may avoid convective heat loss from high-flow vessels </plain></SENT>
<SENT sid="1" pm="."><plain>We evaluated the technical feasibility of and local recurrence following BRFA </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Twenty-two patients undergoing 33 laparoscopic BRFA were identified from September 2007 to April 2009 </plain></SENT>
<SENT sid="3" pm="."><plain>Lesion size, ablation times, morbidity, and pathologic presence of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> after resection were evaluated </plain></SENT>
<SENT sid="4" pm="."><plain>The ablation site recurrence rate is reported with median follow-up time of 24 months (range, 7-42) </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Ablation was performed for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">hepatic metastases</z:e> (CRCHM, n = 17), <z:hpo ids='HP_0001402'>hepatocellular carcinoma</z:hpo> (<z:mp ids='MP_0003331'>HCC</z:mp>, n = 2), gallbladder <z:mp ids='MP_0002038'>carcinoma</z:mp> (n = 2), or <z:hpo ids='HP_0012028'>hepatic adenoma</z:hpo> (n = 1) </plain></SENT>
<SENT sid="6" pm="."><plain>Mean lesion size was 3.6 ± 1.3 cm </plain></SENT>
<SENT sid="7" pm="."><plain>Mean ablation time was 6.6 min, ±2 min, and there was no significant difference in ablation time for lesions &lt;3 cm (5.5 ± 1.7 min) and those &gt;3 cm (7 ± 2.9 min), P = 0.13 </plain></SENT>
<SENT sid="8" pm="."><plain>In each of five CRCHM patients who underwent staged hepatic resection, there was no histologic evidence of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> in ablated areas </plain></SENT>
<SENT sid="9" pm="."><plain>One ablation site recurrence occurred in the CRCHM group </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: BRFA achieves efficient ablation times using line of sight energy delivery </plain></SENT>
<SENT sid="11" pm="."><plain>The short ablation times and the pathologic absence of viable <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> in post-BRFA resected specimens support further study of BRFA as a hepatic ablation method </plain></SENT>
</text></document>